Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures.
Verheul C, Ntafoulis I, Kers TV, Hoogstrate Y, Mastroberardino PG, Barnhoorn S, Payán-Gómez C, Tching Chi Yen R, Struys EA, Koolen SLW, Dirven CMF, Leenstra S, French PJ, Lamfers MLM. Verheul C, et al. Among authors: struys ea. Neurooncol Adv. 2021 Aug 2;3(1):vdab103. doi: 10.1093/noajnl/vdab103. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34595478 Free PMC article.
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Smitt PA, French PJ. Bralten LB, et al. Among authors: struys ea. Ann Neurol. 2011 Mar;69(3):455-63. doi: 10.1002/ana.22390. Ann Neurol. 2011. PMID: 21446021
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV. Suijker J, et al. Among authors: struys ea. Oncotarget. 2015 May 20;6(14):12505-19. doi: 10.18632/oncotarget.3723. Oncotarget. 2015. PMID: 25895133 Free PMC article.
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Chaturvedi A, Goparaju R, Gupta C, Weder J, Klünemann T, Araujo Cruz MM, Kloos A, Goerlich K, Schottmann R, Othman B, Struys EA, Bähre H, Grote-Koska D, Brand K, Ganser A, Preller M, Heuser M. Chaturvedi A, et al. Among authors: struys ea. Leukemia. 2020 Feb;34(2):416-426. doi: 10.1038/s41375-019-0582-x. Epub 2019 Oct 4. Leukemia. 2020. PMID: 31586149 Free PMC article.
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A. Chaturvedi A, et al. Among authors: struys ea. Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31. Leukemia. 2017. PMID: 28232670 Free PMC article.
162 results